Perioperative Use of Continuous Glucose Monitoring for Scheduled Cesarean Deliveries (PERUSE)
NCT: NCT07671599 · NOT_YET_RECRUITING
Brief Summary
This prospective pilot study is exploratory in nature and is designed to evaluate the validity of continuous glucose monitor (CGM) use for perioperative glucose surveillance during scheduled Cesarean delivery for nondiabetic patients. Primary objective is characterization of perioperative glucose trends during elective Cesarean delivery in patients without diabetes and exploratory analyses will describe perioperative glucose patterns captured by CGM. Secondary objective is to examine rates of and associations with post-operative complications, including surgical site infections.
Frequently Asked Questions
What is Perioperative Use of Continuous Glucose Monitoring for Scheduled Cesarean Deliveries (PERUSE)?
Perioperative Use of Continuous Glucose Monitoring for Scheduled Cesarean Deliveries (PERUSE) is a clinical trial registered under NCT07671599. Current status: NOT_YET_RECRUITING.
What is the status of NCT07671599?
The current status of NCT07671599 (Perioperative Use of Continuous Glucose Monitoring for Scheduled Cesarean Deliveries (PERUSE)) is: NOT_YET_RECRUITING.
When did Perioperative Use of Continuous Glucose Monitoring for Scheduled Cesarean Deliveries (PERUSE) start?
Perioperative Use of Continuous Glucose Monitoring for Scheduled Cesarean Deliveries (PERUSE) started on 2026-09.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.